{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05383079\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["lutetium-177 PSMA-I&T","radium-223"]],"indication":"metastatic castration-resistant prostate cancer","name":"AlphaBet","nct_id":"NCT05383079","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alphabet-nct05383079. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AlphaBet","arms":[{"description":"In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-I\\&T on Day 1 of every 6 week Cycle. Radium-223 will be administered concurrently every 6 weeks. The dose of Radium-223 will vary in dose-escalation. Up to 6 Cycles will be given.","label":"Radium-223 and Lutetium-177 PSMA-I&T","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-01","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer","MCRPC","Prostate Cancer"],"enrollment":{"count":36,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lutetium-177 PSMA-I&T","otherNames":[],"type":"DRUG"},{"name":"Radium-223","otherNames":[],"type":"DRUG"}],"last_update":"2025-02-07","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-08-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose Limiting toxicities (DLTs)","timeFrame":"Dose escalation phase is expected to be completed 6 months from the time the first patient is recruited."},{"measure":"Maximum Tolerated dose (MTD)","timeFrame":"Dose escalation phase is expected to be completed 6 months from the time the first patient is recruited."},{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"Up to 30 months from the time the first patient is recruited."},{"measure":"50% Prostate-Specific Antigen Response Rate (PSA-RR)","timeFrame":"Through study completion, up until 12 months after the last patient commences treatment"}],"references":[{"citation":"Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS. Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial. Lancet Oncol. 2025 Nov;26(11):1479-1488. doi: 10.1016/S1470-2045(25)00559-5. Epub 2025 Oct 18.","pmid":"41119954","type":"DERIVED"},{"citation":"Kostos L, Buteau JP, Yeung T, Iulio JD, Xie J, Cardin A, Chin KY, Emmerson B, Owen KL, Parker BS, Fettke H, Furic L, Azad AA, Hofman MS. AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med (Lausanne). 2022 Nov 18;9:1059122. doi: 10.3389/fmed.2022.1059122. eCollection 2022.","pmid":"36465905","type":"DERIVED"}],"start_date":{"date":"2022-09-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT05383079"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alphabet-nct05383079"}